Assistant Professor, Pharmacotherapy
Department of Pharmacy Practice
College of Pharmacy
Oregon Health & Science University
3303 SW Bond Ave., CH12C
Portland, OR 97239
Phone: 503-494-5976
allenge@ohsu.edu
Fellowship, Infectious Diseases Pharmacotherapy, Wayne State University, Detroit, MI, 1999-2001
Pharmacy Practice Residency, University of Washington/Harborview Medical Centers, Seattle, WA, 1998-1999
Pharm.D., Massachusetts College of Pharmacy and Allied Health Sciences, Boston, MA, 1998
B.S., Molecular/Cellular/Developmental Biology, University of New Hampshire, Durham, NH, 1993
George Allen's research focus is infectious diseases, particularly laboratory-based studies of antimicrobial pharmacodynamics and bacterial resistance. His current work includes studies of bacterial resistance to fluoroquinolones, with a specific focus on the mutant prevention concentration (MPC) phenomenon in various organisms, including Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pneumoniae. This research is performed using in vitro modeling techniques, and includes analysis of the genetic basis for fluoroquinolone resistance in these microorganisms. His practice site is the OHSU Medical Center.
Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. International Journal of Antimicrobial Agents. 2004;24:150-60.
Drew RH, for the American College of Clinical Pharmacy Infectious Diseases Practice and Research Network Bibliography Group (Aeschlimann J, Allen GP, Bearden DT, et al). Key references in infectious diseases pharmacotherapy. Pharmacotherapy. 2004;24:1586-93.
Bearden DT, Allen GP. Impact of antimicrobial control programs on patient outcomes: pharmacy perspective. Disease Management and Health Outcomes. 2003;11:723-36.
Allen GP, Kaatz GW, Rybak MJ. The comparative effect of mutant prevention concentration-targeted concentrations of moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2003;47(8):2606-2614.
Allen GP. The mutant prevention concentration (MPC): a review. Journal of Infectious Disease Pharmacotherapy. 2003;6:27-47.
Allen GP, Bearden DT. Fluoroquinolones in outpatient infections: friend or foe? Oregon Drug Use Review Board Newsletter. 2002;4(6):1-2.
Allen GP, Cha RC, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials against multidrug-resistant Staphylococci and Enterococci in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2002;46:2606-2612.
Allen GP, Rybak MJ. The mutant prevention concentration - a novel concept in bacterial resistance. Newsletter of the International Society of Chemotherapy. 2001;5:10-11.
Rybak MJ, Allen GP, Hershberger E. In Vitro Antibiotic Pharmacodynamic Models. Chapter 3. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 1st edition, 2001. New York: Marcel Dekker Inc.
Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activity of LY333328 and vancomycin administered alone or in combination with gentamicin in an in vitro pharmacodynamic infection model against three strains of vancomycin-intermediate Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 2000;44(11):2991-8.
Allen GP, Black D, Hooton TM, Limaye A. Therapeutic considerations of carbapenem antibiotics: Part 2 of a 2-part series. Drug Therapy Topics (University of Washington Medical Center). 1999;28(1):1-4.
Allen GP, Black D, Hooton TM, Limaye A. Therapeutic considerations of carbapenem antibiotics: Part 1 of a 2-part series. Drug Therapy Topics (University of Washington Medical Center). 1998;27(12):59-63.
